On July 2, 2024 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA (Press release, Altimmune, JUL 2, 2024, View Source [SID1234644655]). The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!